{"url_path":"/sec/engn/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270386-index.html","accession_number":"0001193125-26-270386","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270386-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":403,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\nExhibit\n\nNumber\n\nDescription\n\n[3.1](https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-ex3_1.htm)\n\n \n\n[Notice of Alteration, Notice of Articles and Certificate of Change of Name, effective as of April 8, 2026 (incorporated by reference to Exhibit 3.1 of enGene’s Current Report on Form 8-K filed with the SEC on April 9, 2026).](https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-ex3_1.htm)\n\n[3.2](https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-ex3_2.htm)\n\n \n\n[Articles of enGene Therapeutics Inc., as amended April 8, 2026 (incorporated by reference to Exhibit 3.2 of enGene’s Current Report on Form 8-K filed with the SEC on April 9, 2026).](https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-ex3_2.htm)\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1980845/000119312526059479/engn-ex4_1.htm)\n\n \n\n[Form of Indenture (incorporated by reference to Exhibit 4.1 to enGene’s Form S-3 Registration Statement Registration No.: 333- 293597 filed with the SEC on February 19, 2026). ](https://www.sec.gov/Archives/edgar/data/1980845/000119312526059479/engn-ex4_1.htm)\n\n[10.1](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-ex1_1.htm)\n\n \n\n[Sales Agreement, dated March 9, 2026, by and between enGene Therapeutics Inc. and Leerink Partners LLC (incorporated by reference to Exhibit 1.1 of enGene’s Current Report on Form 8-K filed with the SEC on March 9, 2026).](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-ex1_1.htm)\n\n[10.2*#](engn-ex10_2.htm)\n\n \n\n[Second Amended and Restated Employment Agreement, dated February 27, 2026, by and between enGene Inc. and Anthony T. Cheung.](engn-ex10_2.htm)\n\n[10.3*#](engn-ex10_3.htm)\n\n \n\n[Amended and Restated Employment Agreement, dated May 5, 2026, by and between enGene USA, Inc. and Hussein Sweiti.](engn-ex10_3.htm)\n\n[31.1*](engn-ex31_1.htm)\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](engn-ex31_1.htm)\n\n[31.2*](engn-ex31_2.htm)\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](engn-ex31_2.htm)\n\n[32.1*](engn-ex32_1.htm)\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](engn-ex32_1.htm)\n\n[32.2*](engn-ex32_2.htm)\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](engn-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n# Indicates a management contract or compensatory plan or arrangement\n\n \n\n38\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nenGene Therapeutics Inc.\n\nDate: June 15, 2026\n\nBy:\n\n/s/ Ronald H.W. Cooper\n\nName: Ronald H. W. Cooper\n\nTitle: Chief Executive Officer and President\n\n \n\nDate: June 15, 2026\n\nBy:\n\n/s/ Ryan Daws\n\n \n\n \n\n \n\nName: Ryan Daws\n\n \n\n \n\n \n\nTitle: Chief Financial Officer\n\n \n\n \n\n \n\n \n\n \n\n39"}